NEVANAC
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NEVANAC (NEVANAC).
Nepafenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, primarily COX-2, reducing prostaglandin synthesis and thereby suppressing ocular inflammation and pain.
| Metabolism | Nepafenac is metabolized via ocular tissues to amfenac, the active metabolite. Systemic metabolism primarily involves hepatic conjugation and oxidation. |
| Excretion | Nepafenac is extensively metabolized, primarily via hydrolysis to amfenac. Renal excretion accounts for approximately 85% of the administered dose, with about 13% excreted as unchanged nepafenac and amfenac in urine. Fecal elimination is minimal. |
| Half-life | The terminal elimination half-life of nepafenac is approximately 12.5 hours in plasma, while its active metabolite amfenac has a half-life of about 24 hours. This supports twice-daily dosing. |
| Protein binding | Nepafenac is approximately 98% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | The apparent volume of distribution (Vd/F) is approximately 0.6 L/kg (range 0.5-0.7 L/kg), suggesting distribution into total body water and some tissue binding. |
| Bioavailability | Ophthalmic: Systemic bioavailability after topical ocular administration is very low (approximately 0.1-1% of the dose), but sufficient for local ocular effects. Oral bioavailability is not clinically relevant as drug is only used ophthalmically. |
| Onset of Action | Ophthalmic: Analgesic effect and reduction of inflammation occur within 1-2 hours post-instillation. |
| Duration of Action | The clinical effect lasts approximately 12-16 hours, supporting twice-daily dosing. Duration may be extended with continued use. |
One drop of 0.1% ophthalmic suspension instilled into the affected eye(s) three times daily.
| Dosage form | SUSPENSION/DROPS |
| Renal impairment | No dose adjustment required in renal impairment; systemic exposure is minimal due to topical administration. |
| Liver impairment | No dose adjustment required in hepatic impairment; systemic exposure is minimal. |
| Pediatric use | Safety and efficacy in pediatric patients have not been established; use is not recommended. |
| Geriatric use | No specific dose adjustment; dosing is identical to standard adult dosing. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for NEVANAC (NEVANAC).
| Breastfeeding | No data on nepafenac in breast milk. Ophthalmic administration yields negligible systemic concentrations. M/P ratio not determined. Considered likely compatible with breastfeeding due to minimal absorption, but caution advised. |
| Teratogenic Risk | Nepafenac is an NSAID. First trimester: limited human data, but NSAIDs as a class are associated with increased risk of spontaneous abortion and cardiac defects. Second trimester: generally considered lower risk for teratogenicity, but avoid if possible. Third trimester: increased risk of premature closure of the ductus arteriosus, oligohydramnios, and fetal renal impairment. Ophthalmic use results in minimal systemic absorption, but theoretical risks remain. Use only if clearly needed. |
■ FDA Black Box Warning
No FDA black box warning.
| Common Effects | Decreased vision Foreign body sensation in eyes Increased intraocular pressure Stickiness |
| Serious Effects |
["Hypersensitivity to nepafenac or any component of the formulation","History of asthma, urticaria, or allergic-type reactions to aspirin or other NSAIDs"]
| Precautions | ["Increased bleeding time due to antiplatelet effect","Delayed healing or corneal adverse events including keratitis and corneal perforation","Cross-sensitivity with aspirin or other NSAIDs","Use with caution in patients with bleeding diatheses or concurrent anticoagulants"] |
Loading safety data…
| Fetal Monitoring | Monitor for maternal signs of NSAID-related adverse effects (gastrointestinal bleeding, renal impairment, hypertension) if used systemically. Fetal monitoring in third trimester: assess amniotic fluid volume, ductus arteriosus patency via ultrasound if prolonged use or exposure near term. |
| Fertility Effects | NSAIDs may impair female fertility by inhibiting prostaglandin synthesis, potentially delaying or preventing ovulation. Reversible upon discontinuation. No specific data for nepafenac. |